Diamond Biotechnology Bilan de santé
Santé financière contrôle des critères 4/6
Diamond Biotechnology has a total shareholder equity of NT$612.6M and total debt of NT$301.9M, which brings its debt-to-equity ratio to 49.3%. Its total assets and total liabilities are NT$1.0B and NT$428.9M respectively. Diamond Biotechnology's EBIT is NT$98.7M making its interest coverage ratio 13.6. It has cash and short-term investments of NT$224.1M.
Informations clés
49.3%
Ratio d'endettement
NT$301.86m
Dette
| Ratio de couverture des intérêts | 13.6x |
| Argent liquide | NT$224.14m |
| Fonds propres | NT$612.55m |
| Total du passif | NT$428.90m |
| Total des actifs | NT$1.04b |
Mises à jour récentes de la santé financière
Pas de mise à jour
Recent updates
Analyse de la situation financière
Passif à court terme: 6815's short term assets (NT$673.3M) exceed its short term liabilities (NT$231.8M).
Passif à long terme: 6815's short term assets (NT$673.3M) exceed its long term liabilities (NT$197.1M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 6815's net debt to equity ratio (12.7%) is considered satisfactory.
Réduire la dette: 6815's debt to equity ratio has increased from 37.8% to 49.3% over the past 5 years.
Couverture de la dette: 6815's operating cash flow is negative, therefore debt is not well covered.
Couverture des intérêts: 6815's interest payments on its debt are well covered by EBIT (13.6x coverage).